Tada Medical is a spin-off from the Clinical Innovation Fellowships (CIF) programme born with the purpose of creating solutions for the unmet needs of hospitals across the globe. During the programme, the founders spent eight intense months at the Children’s department for Blood and Tumour diseases at the Uppsala University Children's Hospital. During this time, the pressing need to increase the safety of IV therapy for patients and healthcare professionals by preventing IV catheter dislodgement was identified and the breakaway concept behind the solution was developed. The company was founded in May 2016, and the team has, since that day, persistently fought to bring their first product ReLink® to the market. Intravenous (IV) therapy is the most common invasive treatment in the world received by 80% of in-hospital patients. Up to 36% of all IV tubes are accidentally ripped from the patient’s vein during treatment, resulting in consequences such as loss of medication, interrupted therapy, patient injury, and increased personnel workload. IV tubes cannot be reused and must be discarded if they are ripped out accidentally. This generates about 22,800 tons of plastic waste in Europe and the US per year. We have a patented, low-cost, simple to use safety solution to this massive global problem. Our innovation ReLink® is a breakaway connector to be placed on the IV tubes. It consists of two parts held together by a weak-link solution designed to release when the connector is subjected to a specific pull force. Double valves keep liquid from spilling when the parts are pulled apart. After separation, the parts can be cleaned and reconnected to rapidly reinstate therapy. The Tada core team includes an operational team of employees and interns as well as both inhouse consultants and advisors/investors who are all dedicated to our cause. Tada Medical has participated in exhibitions, trade fairs and pitch events and is an active member of several networks both in Sweden and in Europe. In the spring of 2020, Tada won the H2020 EIC Accelerator (961967) and were approved funding through the programme.